Vicore Pharma Holding AB
NASDAQTotal Valuation
Vicore Pharma Holding AB carries a market capitalization of 249.99M, placing it among publicly traded companies globally. Its enterprise value stands at -905.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 249.99M |
| Enterprise Value | -905.64M |
Share Statistics
Vicore Pharma Holding AB currently has 281.53M shares outstanding.
| Shares Outstanding | 281.53M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Vicore Pharma Holding AB maintains a current ratio of 12.68, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.68 |
| Quick Ratio | 12.68 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -44.35 |
Financial Efficiency
| Return on Equity (ROE) | -44.11 |
| Return on Assets (ROA) | -40.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 259,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Vicore Pharma Holding AB's stock has declined approximately -45.53846% over the past 52 weeks. The 50-day moving average sits at 10.62, while the 200-day moving average is 11.17.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.53846% |
| 50-Day Moving Average | 10.62 |
| 200-Day Moving Average | 11.17 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Vicore Pharma Holding AB generated 3.23M in revenue and converted that into -388.56M in net income, yielding earnings per share of -14.75. EBITDA reached -407.66M, while operating income came in at -407.66M.
| Revenue | 3.23M |
| Gross Profit | 3.23M |
| Operating Income | -407.66M |
| Pretax Income | -388.30M |
| Net Income | -388.56M |
| EBITDA | -407.66M |
| EBIT | -407.66M |
| Earnings Per Share (EPS) | -14.75 |
Balance Sheet
Total book value stands at 853.63M, with working capital of 853.06M providing operational flexibility.
| Cash & Cash Equivalents | 905.64M |
| Total Debt | N/A |
| Net Debt | -428.59M |
| Equity (Book Value) | 853.63M |
| Book Value Per Share | 3.03 |
| Working Capital | 853.06M |
Cash Flow
Vicore Pharma Holding AB produced -355.04M in operating cash flow over the past twelve months.
| Operating Cash Flow | -355.04M |
| Capital Expenditures | N/A |
| Free Cash Flow | -355.04M |
| FCF Per Share | -13.48 |
Margins
Vicore Pharma Holding AB operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -12,605.32 and net profit margin of -12,014.94 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -12,605.32 |
| Pretax Margin | -12,006.93 |
| Profit Margin | -12,014.94 |
| EBITDA Margin | -12,605.32 |
Scores
Vicore Pharma Holding AB posts an Altman Z-Score of -0.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.34 |